Evaluation of cytokeratin-19 & cytokeratin-20 and interleukin-6 in Egyptian bladder cancer patients

Clinical Biochemistry

Volumn 35, Issue 8, 2002, Pages 607-613

  El Salahy, Eman Mahmoud ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bilharziasis; Cystitis; Cytokeratin 19; Cytokeratin 20; Interleukin 6; Reverse Transcriptase Polymerase Chain Reaction; Squamous Cell Carcinoma; Transitional Cell Carcinoma

Indexed keywords

CYTOKERATIN 19; CYTOKERATIN 20; INTERLEUKIN 6; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCHISTOSOMIASIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; EGYPT; GENETIC MARKERS; HUMANS; INTERLEUKIN-6; INTERMEDIATE FILAMENT PROTEINS; KERATIN-20; KERATINS; MIDDLE AGED; SCHISTOSOMIASIS; URINARY BLADDER NEOPLASMS;

EID: 0036867042     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(02)00382-X     Document Type: Article

References (46)

1. Al-Sheikh A., Mohamed A., Jones E., Masterson J., Gilks C.B. Comparison of the WHO/ISUP classification, and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. J Med Pathol. 14:(4):2001;267-272.
2. Bauer J., Ganter U., Geiger T. Regulation of interleukin-6 expression in cultured human blood monocytes, and monocyte derived macrophages. Blood. 72:1988;1134-1140.
3. Berman R., Suzuki H., Tahara P., Robbins S., Narula, Lotze M. Systemic administration of cellular IL-10 induces an effective specific, and long-lived immune response against established tumors in mice. J Immunol. 157:1996;231.
4. Blankenstein T.Z., Qin K., Uberla W., Muller H., Rosen H., Volk, Diamantstein T. Tumor suppression after tumor cell-targeted tumor necrosis factor a gene transfer. J Exp Med. 173:1991;1047.
5. Buchumensky V., Klein A., Zemer R., Kessler O., Zimlichman S., Nissenkorn I. Cytokeratin 20 A new marker for early detection of bladder cell carcinoma . J Urology. 160:1998;1971-1974.
6. Burchill S., Bradbury M., Plttman K., Soughate J., Smith B., Selby P. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase polymerase chain reaction. Br J Cancer. 71:1995;278-281.
7. Carbayo M., Espasa A., Chinchilla V., Herrero E., Megias J., Mira A., Soria F. New electrochemiluminescent immunoassay for the detection of CYFRA21-1 Analytical evaluation, and clinical diagnostic performance in urine samples of patients with bladder cancer . Clinical Chemistry. 45:(10):1999;1944-1953.
8. Cardillo M., Sale P., Silverio F. Heat shock protein-90, IL-6, and IL-10 in bladder cancer. J Anticancer Res. 20:(6B):2000;4579-4583.
9. Colombo M., Forni G. Cytokine gene transfer in tumor inhibition, and tumor therapy where are we now? Immunol Today. 15:1994;48.
10. Colombo M.P., Ferrari A., Stoppacciaro M., Parenza M., Rodolfo F., Mavilio G., Parmiani G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med. 173:1991;189.
11. Columbek P.T., Azhari M., Elizabeth H.I., Levitsky A., Lazenby K., Leong D.M., Pardoll. Controlled release, biodegradable cytokine depots a new approach in cancer vaccine design . Cancer Res. 53:1993;5841.
12. Desai S., Lim S.D., Jimenez R.E., Chun T., Keane T.E., McKenney J.K., Zavala Pompa A., Cohen C., Young R.H., Amin M.B. Relationship of cytokeratin 20, and CD44 protein expression with WHO/ISUP grade in pTa, and pT1 papillary urothelial neoplasia. J Med Pathol. 13:(12):2000;1315-1323.
13. Ferrantini M., Proietti L., Santodonato L., Gabriele M., Peretti I., Plavec F., Meyer T., Kaido I., Gresser, Belardelli F. α-interferon gene transfer into metastatic friend leukemia cells abrogated tumorigenicity in immunocompetent mice antitumor therapy by means of interferon-producing cells . Cancer Res. 53:1993;1107.
14. Fuchs F. Keratins as biochemical markers of epithelia differentiation. Trends Genet. 4:1988;277-281.
15. Gansbacher B., Bannerji B., Daniels K., Zier K., Cronin, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent, and long lasting antitumor immunity. Cancer Res. 50:1990;7820.
16. Ghoneim M., El-Mekresk M., El-Baz M., El-Attar I., Ashamallah A. Radical cystectomy for carcinoma of the bladder, critical evaluation of the results in 1026 cases. J Urol. 158:1997;393-399.
17. Golijanin D., Shapiro A., Pode D. Immunostaining of CK-20 in cells from voided urine for detection of bladder cancer. J Urol. 164:(6):2000;1922-1927.
18. Gudemann C.J., Weitz J., Kienle P., Lacroix J., Wiesel M.J., Soder M., Benner, Staehler G., Doeberitz M.V. Detection of hematogenous micrometastases in patients with transitional cell carcinoma. J Urol. 164:(2):2000;532-536.
19. Henderson R. Assessing test accuracy, and its clinical consequences a primer for receiver operating characteristic curve analysis . Ann Clin Biochem. 30:1993;521-539.
20. + T cell-dependent tumor rejection. J Exp Med. 174:1991;1291.
21. Jiang J., Ulbright T.M., Younger C., Sanchez K., Bostwick D.G., Koch M.O., Eble J.N., Cheng L. Cytokeratin 7, and cytokeratin 20 in primary urinary bladder carcinoma, and matched lymph node metastasis. J Arch Pathol Lab Med. 125:(7):2001;21-24.
22. Kahan E., Ibrahim A., El-Najjar K., Ron E., Al-Agha H., Polliack A., El-Bolkainy M. Cancer pattern in the Middle East: Special report from the Middle East Cancer Society. Acta Oncol. 1997;631-636.
23. Kaneda T., Hoshi S., Mao H., Takahashi T., Suzuki K., Sato M., Orikasa S. Detection of urogenital malignant cells in the peripheral blood by nested RT-PCR using keratin 19 mRNA. Jpn J Urology. 89:(1):1998;33-42.
24. Klein A., Zemer R., Buchumensky V., Klaper R., Nissenkorn. Expression of Cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer. 82:(2):1998;349-354.
25. Lin S., Hirschowitz S.L., Williams C., Shintako P., Said J., Rao J.Y. Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology preliminary retrospective study on archived urine slides . Cancer Detection, and Prevention. 25:(2):2001;202-209.
26. McBride W.H., Dougherty G.D., Wallis A.E., Economou J.S., Chiang C.S. Interleukin-3 in gene therapy of cancer. Folia Biol. 40:1994;62.
27. Mokhtar N. Cancer pathology Registry 1985-1989, National Cancer Institute, Cairo University. 1991;12-19 Department of Pathology, Natl. Cancer Inst. Al-Asdkaa G. C. Cairo.
28. Moll R., Franke W., Schiller D. The catalog of human cytokeratins Patterns of expression in normal epithelia, tumors, and cultured cells . Cell. 31:1982;11-24.
29. Morita T., Kikuchi T., Hashimoto S., Kobayashi Y., Tokue A. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer. J Eur Urol. 32:(2):1997;237-244.
30. Moshira M., Rehab M., Sanna E., Mohamed S., Kawther A., Khalifa A. Evaluation of TGFβ1, DNA pattern, SPF, MI, AL, in patients with bladder cancer. Intl J of CMBR. 8:(3):2001;1651-1670.
31. Mullen C.A., Coale M.M., Levy A.T., Stetler- Stevenson W.G., Liotta L.A., Brandt S., Blaese R.M. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 52:1992;6020.
32. Musiani A., Allione A., Modica P.L., Lokkini M., Giovarelli F., Cavallo F., Belardelli G., Forni, Modesti A. Role of neutrophils, and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, TNF-α, TNF-β, and TNF-γ Lab Invest. 74:1996;146.
33. Nakashima E.A., Oya Y., Kubota N., Kanada R., Matsushita K., Takeda F., Ichimura K., Kuno N., Mukaida K., Hirose. A candidate for cancer gene therapy MIP-1a gene transfer to an adenocarcinoma cell line reduced tumorigenicity, and induced protective immunity in immunocompetent mice . Pharm Res. 13:1996;1896.
34. Okamoto M., Hattori K., Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer. 72:(1):1997;149-154.
35. Pariente J.L., Bordenave L., Jacob F., Gobinet A., Leger F., Ferriere J.M., LeGuillou M. Analytical, and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J Urol. 163:(4):2000;1116-1119.
36. Raghaven D., Shipley W., Garnick M., Russell P., Richie J. Biology, and management of bladder cancer. New Engl J Med. 322:1990;1129-1135.
37. Rastel D. Measurement of cytokeratin 19 fragments in serum clinical application of a tumor marker called CYFRA21-1 . Tumor Marker Update. 7:1995;55-63.
38. Rotem D., Cassel A., Lindenfeld N., Mecz Y., Sova Y., Resnick M., Stein A. Urinary cytokeratin 20 as a marker for transitional cell carcinoma. J Eur Urol. 37:(5):2000;601-604.
39. Sherif M., Ibrahim A. The profile of cancer in Egypt. 1987;Arab World Printing House, Cairo.
40. Southgate J., Harnden P., Trejdosiewicz L. Cytokeratin expression patterns in normal, and malignant urothelium a review of the biological, and diagnostic implications . J Histol Histopathol. 14:(2):1999;657-664.
41. Southgate J., Hutton K., Thomas D., Trejdesiewicz L. Normal human urothelial cells in vitro proliferation, and induction of stratification . Lab Invest. 71:1994;583-594.
42. Stieber P., Schmeller N., Schambeck C.H., Fateh-Moghadam A. Clinical relevance of CYFRA21-1, TPA-IRMA, and TPA-LIA-mat in urinary bladder cancer. Anticancer Res. 16:1996;3793-3798.
43. Tepper R.I., Pattengale P.K., Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 57:1989;503.
44. Trinchieri G., Scott P. The role of interleukin 12 in the immune response, disease, and therapy. Immunol Today. 15:1994;460.
45. Watanabe Y., Kuribayash K., Matsushima K., Nishihara E., Nakayama T., Taniyama, Sakata T. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Prac Natl Acad Sci USA. 86:1989;9456.
46. World Health Organization. Tropical diseases. Technical Report Series No. TDR/CTDY/HH 90.1, Geneva. WHO 1990.